111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
肝细胞癌伴Ⅰ - Ⅱ型门静脉癌栓患者行肝切除术与靶向治疗联合 PD - 1 抑制剂治疗的比较研究
Authors Li L, Li Z, Zhang Y, Zhu S, Ni Y, Xu L, Yan S, Tang Y
Received 6 October 2025
Accepted for publication 9 December 2025
Published 16 December 2025 Volume 2025:12 Pages 2745—2754
DOI https://doi.org/10.2147/JHC.S571169
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Imam Waked
Liang Li,1,2,* Zhenli Li,1,3,* Yibing Zhang,4,* Shuaishuai Zhu,1 Yuanzhi Ni,1,5 Lindi Xu,1,2 Shixing Yan,1,2 Yufu Tang1
1Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, Shenyang, People’s Republic of China; 2Graduate School, Dalian Medical University, Dalian, People’s Republic of China; 3Department of General Surgery, the 963rd Hospital of the Joint Service Support Force of the PLA, Jiamusi, People’s Republic of China; 4Department of Medical Affairs, General Hospital of Northern Theater Command, Shenyang, People’s Republic of China; 5Graduate School, China Medical University, Shenyang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yufu Tang, Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, Shenyang, 110000, People’s Republic of China, Email tangyufu0227@163.com
Purpose: The optimal therapeutic strategy of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is debated. This study aimed to compare the survival outcomes of liver resection (LR) versus targeted therapy plus programmed death-1 (PD-1) inhibitors in HCC patients with PVTT.
Patients and Methods: The data of 53 patients with HCC and type I–II PVTT was retrospectively assessed. Among them, 23 underwent LR, and 30 received targeted therapy plus PD-1 inhibitors (TT + PD-1). The baseline characteristics, overall survival (OS) and progression-free survival (PFS) of the two groups were compared. Univariable and multivariable Cox regression analysis were performed to identify independent prognostic factors of OS and PFS.
Results: There were no significant differences in baseline characteristics between the LR and TT + PD-1 groups. The LR group showed a significantly superior median OS (27.3 vs 15.3 months; P < 0.001) and PFS (13.8 vs 7.5 months; P = 0.008) compared to the TT + PD-1 group. Multivariable Cox regression analysis identified LR was independently associated with a better OS and PFS.
Conclusion: LR may represent an effective therapeutic option for HCC patients with type I–II PVTT.
Keywords: hepatocellular carcinoma, portal vein tumor thrombus, liver resection, targeted therapy, PD-1 inhibitors
1Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, Shenyang, People’s Republic of China; 2Graduate School, Dalian Medical University, Dalian, People’s Republic of China; 3Department of General Surgery, the 963rd Hospital of the Joint Service Support Force of the PLA, Jiamusi, People’s Republic of China; 4Department of Medical Affairs, General Hospital of Northern Theater Command, Shenyang, People’s Republic of China; 5Graduate School, China Medical University, Shenyang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yufu Tang, Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, Shenyang, 110000, People’s Republic of China, Email tangyufu0227@163.com
Purpose: The optimal therapeutic strategy of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is debated. This study aimed to compare the survival outcomes of liver resection (LR) versus targeted therapy plus programmed death-1 (PD-1) inhibitors in HCC patients with PVTT.
Patients and Methods: The data of 53 patients with HCC and type I–II PVTT was retrospectively assessed. Among them, 23 underwent LR, and 30 received targeted therapy plus PD-1 inhibitors (TT + PD-1). The baseline characteristics, overall survival (OS) and progression-free survival (PFS) of the two groups were compared. Univariable and multivariable Cox regression analysis were performed to identify independent prognostic factors of OS and PFS.
Results: There were no significant differences in baseline characteristics between the LR and TT + PD-1 groups. The LR group showed a significantly superior median OS (27.3 vs 15.3 months; P < 0.001) and PFS (13.8 vs 7.5 months; P = 0.008) compared to the TT + PD-1 group. Multivariable Cox regression analysis identified LR was independently associated with a better OS and PFS.
Conclusion: LR may represent an effective therapeutic option for HCC patients with type I–II PVTT.
Keywords: hepatocellular carcinoma, portal vein tumor thrombus, liver resection, targeted therapy, PD-1 inhibitors